The Efficacy and Safety of Rexmyelocel-T to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM


Original post, click here

Verified May 2017 by Rexgenero Limited

Sponsor:

Collaborator:

Andalusian Initiative for Advanced Therapies – Fundación Pública Andaluza Progreso y Salud

Information provided by (Responsible Party):

Rexgenero Limited

ClinicalTrials.gov Identifier:

NCT03174522

First received: May 31, 2017

Last updated: June 1, 2017

Last verified: May 2017

This trial is a pivotal, placebo-controlled, double-blind, parallel-group, adaptive trial conducted in subjects with DM and CLI Rutherford Category 5. Minimisation will be used to assign eligible subjects in a 2:1 ratio to receive a single intra-arterial administration of Rexmyelocel‑T or matching placebo into the index limb.

Peripheral Arterial Disease (PAD)
Diabetes Mellitus (DM)
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Cardiovascular Disease
Critical Limb Ischemia (CLI)
Drug: Rexmyelocel-T
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: The Efficacy and Safety of Intra-arterial Administration of Rexmyelocel-T to Treat Ischemic Ulcers in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial

Primary Outcome Measures:

Estimated Enrollment: 78
Actual Study Start Date: April 5, 2017
Estimated Study Completion Date: December 30, 2019
Estimated Primary Completion Date: December 30, 2018 (Final data collection date for primary outcome measure)
Experimental: Rexmyelocel-T

Rexmyelocel-T is a cell suspension of autologous bone marrow mononuclear cells (BM-MNCs) composed of several mature cell types.

Drug: Rexmyelocel-T

Rexmyelocel-T is administered through an intra-arterial catheter.

Placebo Comparator: Placebo

The final formulation of the placebo will be a diluted suspension of red blood cells.

Drug: Placebo

Placebo is administered through an intra-arterial catheter.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

INCLUSION CRITERIA:

  1. Aged ≥ 18 to ≤ 85 years.
  2. Diagnosis of Type I or II DM, established more than one year ago.
  3. Glycosylated hemoglobin (HbA1c) < 9%.
  4. Subjects with poor or no (surgical or endovascular) revascularization option classified as CLI Rutherford Category 5. For these patients, one of the following must be confirmed and documented at screening:

    • Ankle systolic pressure < 70 mmHg, or
    • Toe systolic pressure < 50 mmHg, or
    • TcpO2 < 30 mmHg (lying down). Subjects with non-compressible or calcified vessels must qualify on toe pressure or tcpO2.

    Poor or no revascularization option means that, in the opinion of the Investigator, revascularization using surgical or endovascular methods are not feasible due to for example the anatomy of existing vessels and/or existing comorbidity and/or previously failed surgical or endovascular revascularization.

  5. In the opinion of the Investigator, the subject is controlled on medical therapy indicated for CLI (unless there is a documented contraindication or intolerance) and pain management is optimized. Women of childbearing potential must have a negative pregnancy test at screening. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Men and women who are sexually active shall use effective contraceptive methods for the duration of their participation in this study if the partner of the male participant, or if the female participant is of childbearing potential. Effective contraceptive methods are e.g.:

    • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal),
    • Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable),
    • Intrauterine device (IUD),
    • Intrauterine hormone-releasing system (IUS),
    • Bilateral tubal occlusion,
    • Vasectomised partner, or
    • Sexual abstinence. The use of this contraceptive method should be continued for at least the duration of participation in the study, and should be continued thereafter as long as indicated by the study doctor.

EXCLUSION CRITERIA:

Subjects meeting any of the following criteria must not be enrolled in the trial:

  1. Advanced CLI defined as presence of major tissue loss as significant ulceration/gangrene proximal to the metatarsal heads (CLI Rutherford Category 6). Significant ulceration/gangrene means any ulceration that extends beyond the subcutaneous tissue layer, or any gangrene or tissue necrosis proximal to the metatarsal heads.
  2. CLI Rutherford Category 4.
  3. Uncontrolled or untreated proliferative retinopathy.
  4. Failed surgical or endovascular revascularization on the index leg within 10 days after the procedure.
  5. Subjects in whom arterial insufficiency in the lower extremity is the result of acute limb ischemia or an immunological or inflammatory or non-atherosclerotic disorder (e.g., thromboangiitis obliterans (Buerger’s Disease), systemic sclerosis (both limited and diffuse forms).
  6. Clinical evidence of invasive infection on index leg defined as major tissue loss at the mid-foot or heel involving tendon and/or bone, and/or when intravenous antibiotics are required to treat the infection according to the Investigator.
  7. At screening, the presence of only neuropathic ulcers on the index leg.
  8. Amputation at or above the talus on the index leg.
  9. Planned major amputation within the first month after randomization.
  10. On the index leg, use of concomitant wound treatments not currently approved for ischemic wound-healing within 30 days prior to screening or plans to initiate new, nonstandard-of-care treatments to the index leg during the trial.
  11. Blood clotting disorder not caused by medication (e.g., thrombophilia).
  12. Severe hypertension according to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. (34)
  13. A platelet count < 50,000/μL.
  14. International normalized ratio (INR) > 1.5.
  15. Evidence of moderate to severe hepatocellular dysfunction according to the treating physician.
  16. Positive test for human immunodeficiency virus 1 (HIV 1), HIV 2, hepatitis B virus (HBV), hepatitis C virus (HCV) or Treponema pallidum.
  17. Subjects who may not be healthy enough to successfully complete all protocol requirements including BM collection, or who are not expected to survive more than 12 months, or in whom results may be particularly difficult to assess, as assessed by the Investigator. For example:

    1. Concurrent severe congestive heart failure (New York Heart Association Classes III and IV).
    2. Life-threatening ventricular arrhythmias, unstable angina (characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged duration), and/or myocardial infarction within four weeks before screening.
    3. Coronary artery bypass grafting or percutaneous coronary intervention within one month before screening.
    4. A renal and/or carotid revascularization procedure within one month of screening.
    5. Transient ischemic attack within three months prior to screening.
    6. Deep vein thrombosis within three months prior to screening.
    7. Subjects with immunocompromised conditions, organ transplant recipients and/or subjects in need of immunosuppressive therapy.
    8. Neurological dementia (i.e., Alzheimer’s Disease).

17. Subjects who participate in another clinical interventional trial.

18. Subjects who have been treated with experimental medication within 30 days of screening.

19. Subjects who participated in other cell therapy trials for CLI.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03174522

First site: Hospital Reina Sofía de Córdoba
Cordoba, Córdoba, Spain, 14004
Contact: Jose García-Revillo, MD         
Contact: Antonio Chacón, MD         

Rexgenero Limited

Andalusian Initiative for Advanced Therapies – Fundación Pública Andaluza Progreso y Salud

Study Director: Edwin Wagena, PhD Rexgenero Limited

Responsible Party: Rexgenero Limited
ClinicalTrials.gov Identifier: NCT03174522     History of Changes
Other Study ID Numbers: REX-001-004_CLI 5
Study First Received: May 31, 2017
Last Updated: June 1, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Rexgenero Limited:

Autologous
Bone Marrow-derived Mononuclear Cells (BM-MNCs)
Advanced Therapy Medicinal Product (ATMP)
Tissue-engineered Medicinal Product
Revascularization
Angiogenesis
Vasculogenesis
Arteriogenesis

Additional relevant MeSH terms:

Diabetes Mellitus
Cardiovascular Diseases
Ischemia
Diabetes Mellitus, Type 2
Peripheral Arterial Disease
Peripheral Vascular Diseases
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pathologic Processes
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on June 02, 2017